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Managing schizophrenia has never been a trivial matter. Furthermore, while classical antipsychotics induce extrapyramidal side
eﬀects and hyperprolactinaemia, atypical antipsychotics lead to diabetes, hyperlipidaemia, and weight gain. Moreover, even with
newer drugs, a sizable proportion of patients do not show signiﬁcant improvement. Alstonine is an indole alkaloid identiﬁed as
the major component of a plant-based remedy used in Nigeria to treat the mentally ill. Alstonine presents a clear antipsychotic
proﬁle in rodents, apparently with diﬀerential eﬀects in distinct dopaminergic pathways.The aim of this study was to complement
the antipsychotic proﬁle of alstonine, verifying its eﬀects on brain amines in mouse frontal cortex and striatum. Additionally,
we examined if alstonine induces some hormonal and metabolic changes common to antipsychotics. HPLC data reveal that
alstonineincreasesserotonergictransmissionandincreasesintraneuronaldopaminecatabolism.Inrelationtopossiblesideeﬀects,
preliminary data suggest that alstonine does not aﬀect prolactin levels, does not induce gains in body weight, but prevents
the expected fasting-induced decrease in glucose levels. Overall, this study reinforces the proposal that alstonine is a potential
innovativeantipsychotic, andthatacomprehensiveunderstandingofits neurochemical basismayopen newavenues to developing
newer antipsychotic medications.
1.Introduction
The management ofschizophrenic symptoms hasneverbeen
a trivial matter, further complicated by the low adherence
to treatments and the serious side eﬀects of available drugs.
Classical antipsychotics, blocking D2 dopamine receptors,
lead to extrapyramidal eﬀects related to antagonism in the
nigrostriatal pathway [1], and hyperprolactinaemia due to
antagonism in the tuberoinfundibular pathway [2]. In the
early 1990s a new class of antipsychotics was introduced in
the clinic, with the alleged advantage of causing no or mini-
malextrapyramidal (EPS)sideeﬀects[3,4],andtheresulting
potential to increase treatment adherence. Unfortunately,
however, it is now recognized that atypical antipsychotics
often induce diabetes, hyperlipidaemia and weight gain
[5–7]. For instance, patients on clozapine have a 4 times
higher chance of developing diabetes, hyperglycaemia, and
hyperlipidaemia than patients on classical antipsychotics [8].
The mechanisms by which these metabolic alterations are
produced are not entirely understood [9].
Post marketing surveillance has shown that the so-
calledatypicalantipsychotic drugsareindeedquiteheteroge-
neous pharmacologically, varying in eﬀectiveness, as well as
metabolicandEPSsideeﬀects[10].Itisthoughtthatatypical2 Evidence-Based Complementary and Alternative Medicine
N
N+
O
C
O
O
H H
H
CH3
CH3
Figure 1: Alstonine.
antipsychotics fail to induce signiﬁcant EPS eﬀects due to
their weakened blockade of D2 dopamine (DA) receptors
combined with interactions with various neurotransmitters,
especially serotonin (5HT) and in particular the 5HT1A,
5HT2A and 5HT2C receptors [1]. Accordingly, speciﬁc DA
pathwaysmay be modulated by serotonin receptors, depend-
ing on the presence of serotonergic receptor sub-types [11].
Given that positive and negative symptoms of schizophrenia
are thought to reﬂect an imbalance in DA mesolimbic and
mesocortical pathways [12], and the problems seen with
merely blocking DA receptors, it is an attractive idea that
5HTreceptorscanpreciselymodulatediﬀerentDApathways.
The indole alkaloid alstonine (Figure 1)w a si d e n t i ﬁ e da s
the major component of a plant-based treatment given to
mentally ill patients in Nigeria [13]. Alstonine shows a clear
antipsychotic proﬁle in rodents, closer to atypical than to
classical agents [14]. Apparently, alstonine induces dissim-
ilar eﬀects in dopaminergic pathways: while apomorphine-
inducedstereotypy and amphetamine-induced lethality were
signiﬁcantly reduced by alstonine, suggesting a decrease
in mesolimbic DA, alstonine reversed haloperidol-induced
catalepsy, indicating that nigrostriatal dopamine transmis-
sion is not lessened [14]. Relevant for the treatment of nega-
tive symptoms, alstonine also presents anxiolytic properties,
involving 5HT2A,C receptors, and reverses interaction deﬁcits
induced by MK801 [15, 16].
In order to better understand the basis of alstonine’s
antipsychotic proﬁle, the aim of this study was to verify
alstonine eﬀectson brainamines in mouse frontal cortexand
striatum. Additionally, we examined if alstonine causes the
same hormonal and metabolic changes induced by classical
and atypical antipsychotics.
2.Materialsand Methods
2.1. Plant Material. Mature fruits of Picralima nitida Stampf
Th. et H.Dur. were collected by staﬀ from the Interna-
tional Centre of Ethnomedicine and Drug Development
(InterCEDD) in February and March 2002, in Nnewi,
Anambra state, Nigeria. The plant material was identiﬁed by
comparison with a voucher specimen (UNN/83/07) at the
Department of Pharmacognosy Herbarium of the University
of Nigeria, Nsukka, and authenticated by Mr A. Ozioko of
the Department of Botany of the same university. The fruit
rind was separated, dried, and pulverized. The powdered
materialwassuccessivelyextractedwithn-hexane,methylene
chloride, and methanol. Extracts were concentrated under
vacuum using a rotary evaporator.
2.2. Isolation and Identiﬁcation of Alstonine. Pure alsto-
nine hydrochloride used for this investigation was isolated
from the fruit rind of P. nitida Stampf Th. et H.Dur.
(Apocynaceae). The separations were performed using pH-
zone-reﬁning counter-currentchromatographyaspreviously
described [17]. Brieﬂy, the experiment was performed with
a two-phase solvent system composed of methyl tert-butyl
ether (MtBE)-acetonitrile-water (2:2:3, v/v), where triethy-
lamine (TEA) was added to the upper organic stationary
phase as a retainer, and hydrochloric acid (HCl) to the
aqueous mobile phase as an eluter. The basic organic phase
was used as the stationary phase and the acidic lower
phase was used as the mobile phase. The separation was
initiated by ﬁlling the entire column with the stationary
phase using the LC pump, and then loading the sample.
The sample solution was prepared by dissolving 15.0g of
alkaloidfraction ofthemethylene chlorideextractofP. nitida
in 100mL of a phase mixture consisting of equal volumes
of each phase. The mobile phase was then pumped into
the column at 2mLmin−1 while the column was rotated
at 834rpm in the combined head to tail elution mode
[18, 19]. The absorbance of the eluate was continuously
monitored at 280nm and 4mL fractions were collected. The
pH of each eluted fraction was measured with a pH meter
and fractions were dried using a Speed Vac. Identiﬁcation
of pH-zone reﬁning counter-current chromatography pure
fractions was carried out by using thermospray liquid
chromatography-mass spectrometry (LC-MS) and by TLC
co-elution experiments with reference alstonine samples
provided by InterCEDD, Nsukka, Nigeria.
2.2.1. Drugs. Clozapine was purchased from Sigma Chem-
ical Co. (St Louis, MO, US), and haloperidol was used as
commercial Haldol (Janssen Farmacˆ eutica Ltda, SP, Brazil).
Clozapine was solubilized in HCl (0.1N) and its pH adjusted
to 6.0 with NaOH 0.5N; alstonine and haloperidol were
diluted in water. All drugs were administered intraperi-
toneally (ip) in a volume of 0.1mL/10g of body weight.
2.2.2. Animals. Experiments were performed using male
(CF1) adult albino mice, received from Fundac ¸˜ ao Estadual
de Produc ¸˜ ao e Pesquisa em Sa´ ude (FEPPS) at 2 months of
age (40–45g). Animals were maintained in our own animal
facility under controlled environmental conditions (22 ±
1◦C, 12 h-light/dark cycle, free access to food (Nuvilab CR1)
and water), for at least 2 weeks before the experiments.
T h ep r o j e c tw a sa p p r o v e db yt h eU n i v e r s i t ye t h i c s
committee (approval #2007706) and all procedures were
carried out in accordance with institutional policies on the
handling of experimental animals.Evidence-Based Complementary and Alternative Medicine 3
2.2.3. Brain Amines HPLC-ED Determination. Animals (n =
10) received ip saline or alstonine 1.0mgkg−1,a n d3 0m i n
later were sacriﬁced by decapitation. Brains were rapidly
removedand dissected overdry ice;striatum and frontal cor-
tex were removed, weighed and immediately stored in liquid
nitrogen. Not later than a week following sample collections,
tissueswerehomogenizedin0.1Mperchloricacidbymanual
sonication. DA and its metabolites dihydroxyphenylacetic
acid (DOPAC) and homovanillic acid (HVA), as well as 5-
HT and its metabolite 5-hydroxyindole acetic acid (5-HIAA)
were measured by reverse-phase high performance liquid
chromatography (HPLC) with electrochemical detection, as
described by Felicio et al. [20]. Brieﬂy, the HPLC-ED system
(model 6A; Shimatzu, Kyoto, Japan) consisted of a C-18
column (Shimpak; ODS, Kyoto, Japan), an electrochemical
detector (model 6A; Shimatzu), a sample injector (valve
for 20μl), and an integrator (model 6A Chromatopac;
Shimatzu). Dihydroxybenzylamine (DHBA) was used as the
internal standard, and peak areas of external standard were
used to quantify the sample peaks. The time for each sample
was 28 min. Values are expressed as ng/g tissue weight. The
detection limit was 0.002ng for DA, DOPAC, 5-HT, and 5-
HIAA, and 0.02ng for HVA.
2.2.4. Glycaemia. Experiments were conducted between 9
a.m.and12midday.Groupsofmice(n =5–9)weretreatedip
with saline, clozapine (2.0 and 10.0mgkg−1), and alstonine
(0.5 and 1.0mgkg−1). Food and water were withdrawn
immediately before treatments and glucose measurements
were taken before and 3 hours after drug administration [7],
with a glucometer (Accu-Chek Active Roche), using a blood
drop drawn from the tail.
2.2.5. Body Weight. Mice (n = 8–10) were treated ip for
6 days with saline, haloperidol (0.25mgkg−1), clozapine
(2.0mgkg−1) or alstonine (0.5 and 1.0mgkg−1). The body
weight was measured daily between 12 a.m and 1 p.m.
2.2.6. Prolactin (PRL) Levels. Groups of mice (n = 6–
8) were treated with ip injection of saline, haloperi-
dol (0.25mgkg−1), clozapine (2.0mgkg−1) or alstonine
(1.0mgkg−1). Animals were decapitated 30 minutes after
treatments; the blood was collected and centrifuged for
10 minutes at 5000rpm and serum was stored at −20◦C
until assayed. Plasma PRL levels were measured in duplicate
by radioimmunoassay (RIA), using materials provided by
NIADDK (Bethesda, MD, USA). The intra- and inter-assay
coeﬃcients of variation were 6% and 8%, respectively [21].
2.2.7. Statistical Analysis. HPLC data were evaluated by
independent t-test. Group diﬀerences in glucose and pro-
lactin levels were analyzed by one-way ANOVA, followed by
Duncan; pre and post drug glucose levels were analyzed by
paired t-test. ANOVA with repeated measures followed by
Duncan was used to evaluate weight gain. P-value <.05 was
considered signiﬁcant.
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Figure 2: Dopamine (DA) and its metabolites (DOPAC and HVA)
in mouse frontal cortex (a) and in striatum (b) Mean ± SD. ∗P<
.05, ∗∗P<. 01 when compared with saline, Independent t-test.
3.Results
The eﬀectsofalstonine onbrain amines are shown in Figures
2 and 3. DA levels were decreased (t = 4.96, P<. 01) in
frontal cortex (Figure 2(a)), with a concomitant increase in
DOPAC(t = −2.22, P<. 05)and no change in HVA. DOPAC
levelswere also increased (t = −3.62, P<. 01)in the striatum
(Figure 2(b)), without changes in DA or HVA. 5HT levels
were increased only in the frontal cortex (t = −3.74, P<. 05),
whereas increases in 5-HIAA were seen in frontal cortex (t =
−2.68, P<. 01, Figure 3(a))a n ds t r i a t u m( t = −2.5, P<. 05,
Figure 3(b)).
In control animals, as expected, a fasting-induced de-
crease in glucose levels was observed (t = 4.52, P<. 01).
The fasting-induced hypoglycaemia was absent with both
clozapineandalstoninetreatments (Figure 4).Nodiﬀerences
in body weight gain were observed among treatment groups
(Figure 5). Haloperidol (0.25mgkg−1) markedly increased
(F(3,23) = 12.78, P<. 01) prolactin levels, whereas4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Serotonin (5-HT) and its metabolite (5HIAA) in mouse
frontal cortex (a) and in striatum (b) Mean ± SD. ∗P<. 05, ∗∗P<
.01 when compared with saline, Independent t-test.
clozapine (2.0mgkg−1)a n da l s t o n i n e( 1 . 0m gk g −1)d i dn o t
(Figure 6).
4.Discussion
Improving the eﬀectiveness of antipsychotics appears to
require proper and speciﬁc modulation of the various DA
pathways. For instance, lessened extrapyramidal symptoms
andameliorationofnegativesymptoms observedwithnewer
agents is thought to be consequent to diﬀerential eﬀects on
the striatum and frontal cortex, respectively [10].
Although the behavioural proﬁle of alstonine appears to
be closer to that of newer rather than older antipsychotics,
it nevertheless diﬀers from clozapine in its ability to reverse
MK801-induced hyperlocomotion [15]a n ds o c i a ld e ﬁ c i t
[16], and by lacking epileptogenic properties [22]. An
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unusual mechanism of action for alstonine is also here
suggested by its eﬀects on levels of DA in frontal cortex and
striatum. Lack of changes in HVA levels suggests unchanged
DA metabolism at the synaptic level, whereas increases in
DOPAClevelssuggestsaugmentedintraneuronalcatabolism.
DOPAClevelsareacceptedasareliableindexofintraneu-
ronal DA degradation [23, 24], resulting from intracellular
monoamine oxidase (MAO) activity. However, increases in
DOPAC could also result from increased activity of the
membrane transporter DAT, or even from the inhibition of
the vesicular transporter VMAT2. All of these alternatives
would eventually modulate DA availability at the synapticEvidence-Based Complementary and Alternative Medicine 5
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Figure 6: Eﬀects of alstonine, haloperidol and clozapine on
prolactin levels. Mean ± SD. ∗∗P<. 01 when compared with saline.
ANOVA/Duncan.
level.The observeddecrease in DA levelsin the frontal cortex
may not be signiﬁcant behaviourally since we have recently
shown that alstonine increased social interaction and pre-
vented MK801 social withdrawal in mice [16], two accepted
mouse models for behavioral equivalents of negative-like
symptoms. Although only MAO or DAT inhibitor drugs are
currently known, a direct eﬀect of alstonine on these targets
cannotberuledoutatthispoint.Ongoingauto-radiography
experiments will be useful to clarify this issue. In any case, a
diminished DA availability at the synaptic level is consistent
with alstonine’s ability to counteract amphetamine-induced
stereotypy and/or prevent lethality in amphetamine-treated
groupedmice[14].Althoughatthispointitremains amatter
of speculation, such an unusual neurochemical proﬁle could
open up innovative scenarios for antipsychotics and requires
further scrutiny by speciﬁc experiments.
The HPLC analysis also shows that alstonine induced
increases in 5HT levels in frontal cortex, and of 5HIAA in
frontal cortex and striatum. The suggestion that alstonine
actsas a5HT2A,C inverseagonist[15]iscompatiblewith5HT
and 5HIAA increases, since pre-synaptic 5HT2A,C receptors
modulate 5HT release. 5HT modulation is considered to be
c e n t r a lt ot h ed i ﬀerential proﬁle of newer antipsychotics,
and dopamine modulation by serotonin is now generally
accepted [11, 25–27]. 5HT1A and 5HT2A receptors stimulate
DA release in the cortex, whereas 5HT2C receptors may
inhibit DA in the ventral tegmental area; it has been
suggested that these combined properties could balance the
DAsystemtothebeneﬁtofthemanagementofschizophrenic
symptoms [11].
Ithasbeenrecognized thatamino acidneurotransmitters
may play a signiﬁcant role in schizophrenia [28]. Although
the anxiolytic eﬀects of astonine were not modiﬁed by
previous administration of picrotoxine (GABAA antago-
nist), alstonine prevents the emergence of MK80-induced
hyperlocomotion and social withdraw [15, 16]. Given that
alstonine does not seem to interfere directly with [3H]
glutamate release by cortical synaptosomes [29], the data
is rather consistent with an indirect glutamate modulation,
since 5-HT2 receptores are known to modulate NMDA
glutamatergic transmission [30, 31]. Further studies are
needed to better clarify the eﬀects of alstonine on glutamate
and GABA neurotransmission, and/or the role of these
receptors on the amine changes induced by alstonine.
An extensive clinical trial comparing classical and atypi-
cal antipsychotics (known as CATIE) pointed to weight gain
andhyperglycaemiaasmajorcausesofdiscontinuingtherapy
with thenewer drugs [4]. Althoughtreatment periods longer
than those used here would have to be analyzed, neither
alstonine nor clozapine or haloperidol altered mouse weight
gain with doses eﬀective in relevant behavioural mouse
models. The precise mechanism by which antipsychotics
alter glycemia is not completely clear. However, a number
of candidates have been suggested such as H1 histamine
receptors, 5HT2C receptors, M3 muscarinic receptors, α2
adrenergic receptors and the inhibition of glucose trans-
porters (GLUT) [7, 32]. Animal models of hyperglycemia
appear to have a good correlation with clinically induced
diabetes, and it is noticeable that not only atypical agents
but also by some classic antipsychotic like chlorpromazine
and perphenazine produce hyperglycemia in mice [32]. The
fasting period used in this study induces a clear fall in
the glycaemia levels of control animals, a drop absent in
alstonine- and clozapine-treated mice. The data suggest that
alstonine may share with atypical antipsychotics, such as
clozapine, olanzapine and quetiapine, the unwanted changes
in glucose metabolism. The exact mechanism by which such
alterations occur requires explanation.
Relevant to adherence to treatment, a clear correlation
exists between elevated PRL levelsand DA D2 receptoroccu-
pancy by classical antipsychotics in the tuberoinfundibu-
lar pathway [2]. Although doses of antipsychotics used
in rodents are usually much higher than those used in
schizophrenic patients [7, 33, 34] there is a similar pattern
of antipsychotic-induced prolactin release [35].
Diﬀerent from haloperidol, alstonine and clozapine did
not alter PRL levels, further conﬁrming the atypical proﬁle
of the former and reinforcing its diﬀerential eﬀects on the
dopaminergic pathways.
In conclusion, this study reinforces the opinion that a
comprehensive understanding of the neurochemical basis of
alstonine’s seemingly innovative proﬁle as an antipsychotic
may open new avenues to developing newer medications
useful for the treatment of schizophrenic patients. Consid-
ering the gaps in the understanding of schizophrenia and the
complexity of its neurochemical basis, this study underpins
the value of traditional medical systems in unveiling original
drugs.
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